Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178346 · ClinicalTrials.gov registry record · Phase 3
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
A Phase 3 study of Smoking Cessation, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT01178346: Completed Phase 3 study of Smoking Cessation, sponsored by Nabi Biopharmaceuticals.
NCT01178346 is a Phase 3 study of Smoking Cessation that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 500 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01178346, a Phase 3 study of Smoking Cessation, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
Primary Outcome
QoL and health utilization questionnaires will be used to measure this outcome.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NicVAX vaccine
Study Locations (20)
California
- NicVAX Investigator - Encino
- NicVAX Investigator - Los Alamitos
- NicVAX - Newport Beach
- NicVAX Investigator - San Diego
Florida
- NicVAX Investigator - Brooksville
- NicVAX Investigator - Orlando
- NicVAX Investigator - St. Petersburg
- NicVAX Investigator - Tampa
Minnesota
- NicVAX Investigator - Minneapolis
- NicVAX Investigator - Rochester
Arizona
- NicVAX Investigator - Tucson
Colorado
- NicVAX Investigator - Denver
Idaho
- NicVAX Investigator - Boise
Indiana
- NicVAX - Indianapolis
Louisiana
- NicVAX Investigator - Metarie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
What the finished NCT01178346 record still lists
NCT01178346 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01178346 names 20 study sites across 13 states, led by California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01178346 about?
NCT01178346 is a clinical study titled "Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies". The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
What is the current status of trial NCT01178346?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2010-07. Estimated completion is 2011-11.
What conditions does trial NCT01178346 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT01178346?
The interventions under investigation include: Placebo (BIOLOGICAL), NicVAX vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01178346?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01178346 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01178346's enrollment target sits among peer trials
500 53rd of 188 higher than 132 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia